Skip to content
drillr.ai

IRD

Opus Genetics, Inc.

NASDAQ · USHealthcareBiotechnology
$3.05-6.73%

Price as of Jul 20, 2026

IRD news

Opus Genetics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

    RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV

    Globe Newswire ·

  2. Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

    RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (https://www.globenewswire.com/Tracker?data=m5QKGzGeJtENkI2bVWgDn_mvAm_CEQs9_uTzkt_FodY2IJjZsWhSQKPzgCiFkIJQMoaejJEzWhXpLsnWNNL4UXotDOshW3L65QiJ9ctAeio=) (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the Company will be added as a memb

    Globe Newswire ·

  3. Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to ten non-executive employees who

    Globe Newswire ·

  4. Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

    * Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months * Early signals of functional and structural improvement observed at one month and three months * 12-letter BCVA gain and 23% CST reduction observed in the treated eye at three months * Full cohort data expected in mid-year 2026 RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc (https://www.globenew

    Globe Newswire ·

  5. Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNXb2CN1w&default-theme=true RESEARCH TRIANGLE PARK, N.C., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (https://www.globenewswire.com/Tracker?data=NgPOCp_zBgsolKicOy4wCCVivuwY-mAcijbIieoQGSz2PBAsxVaCCLnbqWY3rSA0lLon_pVM9gHi0-mxaIcK4upOnJdRlWWRya0e6nMQ8yN6xPUz-vqLaaux9kF5jt0ytnYhuD5xZwb6YaRpK-uTaTkwpWx0P7jxCBtBWTrVPFpZeGIgJEiAW

    Globe Newswire ·